Pharmaceuticals

I-Mab Added to FTSE Russell Global Equity Index Series

SHANGHAI and GAITHERSBURG, Md., Sept. 2, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE Global Eq...

2021-09-02 20:00 5782

Elekta acquires Turkish distributor to strengthen market position

STOCKHOLM, Sept. 2, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it has acquired its long-time partner and Turkish distributor of neurosurgery solutions, Özyürek Mümessillik ve Dış Ticaret A.Ş. (Özyürek A.Ş.). The acquisition will improve Elekta's market access in the region and ...

2021-09-02 14:16 4285

CStone announces China's NMPA has accepted its new drug application for sugemalimab in the treatment of stage III NSCLC

* Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal antibody to significantly improve progression-free survival (PFS) in patients with stage III non-small cell lung cancer (NSCLC) without disease progression after concurrent or sequential chemoradiotherapy * The new drug applic...

2021-09-02 08:05 3315

Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline

HONG KONG, Sept. 1, 2021 /PRNewswire/ -- Insilico Medicine is pleased to announce an R&D collaboration with Gray Matter, a longevity biotechnology company focused on peptide-based interventions against cognitive decline, age-related CNS diseases, and aging. This strategic partnership is intended ...

2021-09-01 22:08 2889

Seegene Receives CE-IVD Mark for Use of Combo Swab, a Self-Collection Device with Four COVID-19 Diagnostic Tests

SEOUL, South Korea, Sept. 1, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced on August 20 that it has obtained CE marking for the use of Combo Swab, a self-collection device with four diagnostic assays. Combo Swab is a user-friendly...

2021-09-01 17:40 1571

Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK Cell Therapy

BEIJING and SHANGHAI and BOSTON, Aug. 31, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals ("Jacobio", 1167.HK) announced a strategic investment in the US-based biotech company Hebecell onAugust 31. Jacobio will collaborate with Hebecell to develop thenext-generation natural killer cell therapy based...

2021-08-31 22:05 3689

Jacobio Pharmaceuticals Announces 2021 Interim Results

BEIJING and SHANGHAI and BOSTON, Aug. 31, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals ("Jacobio", 1167.HK) announced its results for the first half of 2021. Investment in R&D for the clinical-stage biotech firm reached175 million yuan (approx. US$27 million) for the half year, up 146 percent ye...

2021-08-31 22:01 4597

Senhwa's Silmitasertib, COVID-19 Drug Candidate, Receives Positive Interim Review from Data Monitoring Committee to Proceed

TAIPEI and SAN DIEGO, Aug. 31, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced that its oral new drug, Silmitasertib, had received a positive feedbac...

2021-08-31 19:00 1564

Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial

* Topical treatment safe and well tolerated in study of healthy volunteers * Full inhibition of lysyl oxidase enzymes achieved in skin with minimal systemic exposure * Collaboration with research team led by Professor Fiona Wood AM planning for trial in patients with established scars to com...

2021-08-31 18:00 1267

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021

* 13 significant clinical milestones achieved year-to-date, including critical positive data readout events for felzartamab (TJ202/MOR202), lemzoparlimab (TJC4), uliledlimab (TJD5), and plonmarlimab (TJM2) and more milestone achievements are expected before the year-end 2021 * Felzartamab (TJ...

2021-08-31 18:00 3398

Harbour BioMed Reports 2021 Interim Results

CAMBRIDGE, Mass.and SUZHOU, China and ROTTERDAM, Netherlands, Aug. 31, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, reported its interim...

2021-08-31 13:47 3647

InnoCare Announces Clearance by U.S. FDA of Clinical Trial of pan-TRK Inhibitor ICP-723

BEIJING, Aug. 30, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a commercial-stage biopharmaceutical company, announced today the Investigational New Drug (IND) clearance of its second-generation pan-TRK inhibitor ICP-723 by the US Food and Drug Administration (FDA) for starting phase I cli...

2021-08-31 08:30 2448

Viva Biotech Announced 2021 Interim Results

Revenue Increased by 419.5% YoY, CRO Business Income Increased by 62.5% YoY, O rderBacklog Recorded a Significant Increase of 72% Financial Highlights for the 6 months ended June 30, 2021: * Revenue amounted to RMB1,026.5 million, representing a year-on-year (YoY) increase of approximately 419...

2021-08-31 01:32 5086

Through CEO of Hanmi Science, CancerRop Issues KRW 20 Billion New Shares for Cooperation with Oxford Vacmedix

SEOUL, South Korea, Aug. 30, 2021 /PRNewswire/ -- CancerRop (180400), a company specializing in precision medicine and molecular diagnostics, announced a jump start in the global vaccine hub for COVID-19 mRNA (messenger ribonucleic acid) with Hanmi Science through20 billion won worth of investmen...

2021-08-30 23:00 3188

Everest Medicines Announces Half-Year 2021 Interim Results

SHANGHAI, Aug. 30, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater C...

2021-08-30 22:15 3991

Everest Medicines Announces Up to HK$100 million Share Repurchase Program

SHANGHAI, Aug. 30, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, today announced t...

2021-08-30 22:03 3437

I-Mab Announces Upcoming Participation at September Conferences

SHANGHAI and GAITHERSBURG, Md., Aug. 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in Septem...

2021-08-30 20:00 1675

Alphamab Oncology Reports 2021 Interim Results and Business Highlights

SUZHOU, China, Aug. 30, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK), announced the company's interim results for the six months ended on June 30, 2021, and highlighted recent progress and upcoming milestones. Dr. Ting Xu, Chairman and CEO of Alphamab Oncology, commented, "In 2021 ...

2021-08-30 10:51 3813

GeneQuantum announces Dr. Yi Xia as Senior Vice President of Statistics and Data Science

SUZHOU, China, Aug. 29, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry leading biopharmaceutical company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announces the appointment of Dr.Yi Xia as Seni...

2021-08-30 10:00 1440

Innovent to Present New Data on Sintilimab and Other Molecules at the European Society for Medical Oncology (ESMO) Congress 2021

SAN FRANCISCO and SUZHOU, China, Aug. 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...

2021-08-30 08:00 3509
1 ... 225226227228229230231 ... 314